GT Biopharma, Inc..
GTBP.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immunotherapies based on its proprietary TriKE® (Tri-specific Killer Engager) technology platform. TriKE® is designed to harness and enhance the body's natural killer (NK) ...Show More
Better Health for All
10
GT Biopharma is a clinical-stage biopharmaceutical company entirely focused on developing therapies for serious diseases such as cancer, myasthenia gravis, and motion sickness.
1
Its TriKE® technology is designed to enhance natural killer (NK) cells for cancer treatment.
2
Interim Phase I/II clinical trial results for GTB-3550 TriKE™ showed up to a 63.7% reduction in bone marrow blast levels in some patients with high-risk myelodysplastic syndromes and acute myeloid leukemia, with 57% of patients experiencing a significant reduction in cancer cell burden.
3
The company's products are designed to provide health benefits, and it has no revenue from products with well-established negative health outcomes.
4
GT Biopharma's R&D investment was $12.4 million in 2022, representing 68% of its operating expenses, with $5.7 million specifically for its immunotherapy pipeline.
5
The company discloses risk factors in its documents and trial details for GTB-3650 are available on clinicaltrials.gov (NCT06594445).
6
The company's operations do not involve health-related patents or intellectual property that would require flexibility considerations, as it relies on licensed patents.
7
Fair Money & Economic Opportunity
0
No evidence available to assess GT Biopharma, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess GT Biopharma, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess GT Biopharma, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-30
GT Biopharma restated its unaudited condensed consolidated balance sheets for June 30, 2020, and September 30, 2020, due to an accounting error regarding an $8,643,000 loss on extinguishment of debt.
1
This constitutes one restatement in the past five years (2021-2025). The company has a Code of Business Conduct and Ethics that applies to all directors, officers, employees, agents, and representatives, and explicitly prohibits bribes, kickbacks, or similar remuneration.
2
However, the policy's training frequency and effectiveness metrics are not detailed. Of the four directors, three are identified as independent, resulting in 75% of the board being conflict-free.
3
Kind to Animals
-80
GT Biopharma, Inc. uses animal models for product testing in ovarian cancer and head and neck cancers, and conducts preclinical animal studies and toxicology.
1
There is no evidence that the company employs non-animal testing methods for product safety and efficacy. The company has no explicit animal testing policy stated, though it adheres to Good Laboratory Practices (GLP) regulations for preclinical and animal studies.
2
The company's research and development expenditures were $1,068,000 in 2017 and $3,868,000 for the nine months ended September 30, 2024, with no specified percentage allocated to animal-free technologies.
3
The company has a collaborative relationship with the Masonic Cancer Center at the University of Minnesota, but there is no evidence of participation in multi-stakeholder initiatives to develop industry-wide animal-free testing standards.
4
The company must comply with FDA regulations, but there is no evidence of active engagement in animal welfare policy improvement or advocacy for higher standards.
5
No War, No Weapons
10
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer.
1
The provided articles indicate that the company's core business is exclusively in the biotechnology and healthcare sectors, with no mention of revenue from arms or defense contracts.
2
Its R&D is focused on immuno-oncology products and cancer treatment, with no evidence of investment in dual-use technologies with military applications.
3
There is no evidence of exposure to controversial or banned weapons. Given its exclusive focus on peace and humanitarian technology (cancer treatment), the company's investment ratio in peace technology versus military technology is 100:0. The articles do not provide information regarding conflict minerals in the supply chain, procurement from conflict-affected areas, or codified ethical red lines related to weapons.
Planet-Friendly Business
0
No specific, concrete data points for GT Biopharma, Inc. (GTBP.US) regarding its planet-friendly business practices were found in the provided articles.
1
The articles either explicitly stated a lack of relevant data for GTBP.US or discussed general industry trends within the biopharmaceutical industry without attributing specific performance metrics or initiatives to the company.
Respect for Cultures & Communities
0
No evidence available to assess GT Biopharma, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess GT Biopharma, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding GT Biopharma, Inc.'s waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.
1